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Of the various environmental risk factors demonstrated to be influential in the inception of childhood asthma, the development of allergic sensitization in early life,[@bib1] followed by wheezing respiratory tract illnesses[@bib2] caused by infection with various respiratory pathogens, appear to be the most consistent and reproducible.[@bib3] It has been shown that allergic sensitization has its greatest effect on recurrent wheezing and asthma when the process occurs in the first few years of life[@bib4], [@bib5], [@bib6] and when it involves development of sensitization to multiple aeroallergens.[@bib5], [@bib6] Thus the strength of its influence appears not to be binary but more quantitative and developmental in nature.

Preschool wheezing illnesses with both viral[@bib7], [@bib8], [@bib9] and bacterial[@bib10], [@bib11], [@bib12] pathogens are also associated with recurrent wheezing and increased asthma risk. Historically, Respiratory syncytial virus (RSV) has been considered the most important respiratory pathogen in producing these long-term lower respiratory sequelae,[@bib13] and more recent data provide additional support for this relationship.[@bib14], [@bib15] Furthermore, animal studies provide mechanistic evidence by which RSV can cause asthma.[@bib16] Treatment trials in preterm infants with palivizumab, an anti-RSV mAb, have demonstrated significant reductions in the development of recurrent wheezing.[@bib17]

With the advent of molecular virology technology during the past few decades, human rhinovirus has been increasingly recognized as a major etiologic factor in preschool wheezing illnesses and a highly significant link with the risk of childhood asthma. Indeed, rhinovirus-induced wheezing illnesses are associated with an approximately 10-fold increase in asthma risk by 6 years of age,[@bib7] and potential mechanisms underlying these developments have been described.[@bib18] Certain rhinovirus species (eg, A and C \> B) might be more virulent, thereby causing more lower respiratory tract illnesses[@bib19], [@bib20], [@bib21], [@bib22] and increased morbidity, which result in emergency department visits and hospitalization.[@bib20], [@bib23] Moreover, the development of recurrent lower respiratory tract symptoms after rhinovirus C infections can occur more frequently in subjects with demonstrable allergic sensitization.[@bib24]

Airway bacteria in early life also influence asthma risk. Colonization with common respiratory pathogens, such as *Streptococcus pneumoniae*, *Moraxella catarrhalis*, and *Haemophilus influenzae*, in early life signals an increased risk for recurrent wheeze and early childhood asthma, and these same pathogens are associated with acute wheezing illnesses in young children. New tools to assess the airway microbiome are shedding additional light on relationships between beneficial versus pathogenic microbes and the risk for acute wheezing and asthma.

This article will expand on the contributions of allergic sensitization and viral and bacterial respiratory tract wheezing illnesses on increased risk for both recurrent preschool wheezing and childhood asthma. When possible, we will emphasize data generated in long-term longitudinal studies that have facilitated etiologic and epidemiologic characterizations.

Viruses, bacteria, and asthma development {#sec1}
=========================================

Early-life viral infections and childhood asthma {#sec1.1}
------------------------------------------------

Our understanding of the role of viral infections in wheezing has expanded with the development and evolution of molecular viral diagnostics. Results from studies using PCR and sequenced-based tests indicate that there is a long list of viruses that can cause upper and lower respiratory tract illnesses ([Table I](#tbl1){ref-type="table"} ),[@bib8], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] and the clinical manifestations of infections with these different viruses are quite similar. Infections can lead to no symptoms at all, cold symptoms, or lower respiratory syndromes, such as pneumonitis, bronchiolitis, and acute wheezing illnesses. The risk of asthma seems to be most closely associated with the occurrence and frequency of virus-induced wheezing illnesses.[@bib7] Other clinical manifestations of acute viral illnesses that are associated with increased risk of asthma include fever and pneumonitis.[@bib4] Table IViruses that can cause wheezing illnessesVirusMajor antigenic groupsRhinovirusA, B, CRSVA, BCoronavirusesNL63, HKU1, OC43, 229EMetapneumovirusA, BParainfluenza virusesI, II, III, IVEnterovirusD68, othersInfluenza virusesA, B, CBocavirusAdenovirusSerotypes 1, 2, 3, 5, 6, 7PolyomavirusWU, KI, Malawi

Nearly all wheezing illnesses in the first few years occur during viral respiratory tract infections, and the viruses most frequently associated with wheezing illnesses are RSV and rhinoviruses.[@bib28] Other viruses that are commonly detected during wheezing illnesses include metapneumovirus, coronaviruses, parainfluenza viruses, and bocaviruses. Coinfections with more than 1 virus are most commonly confirmed in infants and can be associated with more severe symptoms.[@bib8], [@bib30] Prolonged illnesses can be caused by sequential infections with more than 1 virus, infections with a virus followed by a bacterial pathogen, or, less commonly, prolonged infection with a single virus.[@bib31] Adenoviruses are more likely than other respiratory viruses to cause prolonged viral shedding.[@bib32]

RSV {#sec1.2}
---

RSV is an enveloped, nonsegmented, negative-strand RNA virus of the family Paramyxoviridae, and RSV infections are ubiquitous in infancy.[@bib33] RSV has 2 main antigenic groups (A and B). In general, RSV-B infections tend to cause less severe illnesses, but virulence varies considerably with individual strains of RSV, even within the antigenic groups. Most RSV infections cause mild or asymptomatic illnesses; it is estimated that only 9% of infections lead to outpatient clinic visits, and 5% or less of infections lead to hospitalization.[@bib34] Even so, RSV infections are the most common cause of bronchiolitis in the first year of life. Risk factors for RSV-induced bronchiolitis include prematurity; comorbid conditions affecting the heart, lungs, or immune system; and age and season of birth.[@bib35] The peak age for susceptibility to RSV lower respiratory tract infection is at 2 to 3 months of age after neutralizing antibody acquired transplacentally from the mother has waned.

RSV replicates in epithelial cells lining the upper airways and bronchioles and in type I pneumocytes. RSV infections that extend into the lower airways can cause airway narrowing and closure by causing epithelial cell necrosis and inducing cellular inflammation and mucus hypersecretion.[@bib36]

There are several lines of evidence to suggest that more severe RSV infections in early life can contribute to the risk for childhood asthma. First, approximately one third of children with RSV-induced bronchiolitis have recurrent wheezing episodes. In turn, children with recurrent wheezing are at increased risk for subsequent asthma, especially if they have atopic parents or other atopic features.[@bib37] Furthermore, in a large Tennessee Medicaid database children who were born approximately 120 days before the peak RSV season were at increased risk for bronchiolitis and had a corresponding increase in the risk for asthma by age 3.5 to 5.5 years.[@bib15] Similarly, analysis of RSV-induced bronchiolitis in birth cohort studies indicates a positive association with the risk for asthma but not allergic sensitization.[@bib38], [@bib39] Finally, analysis of the Tucson Children\'s Respiratory cohort through young adulthood revealed an interaction between RSV lower respiratory tract infection in infancy and smoking with respect to asthma. Active smoking was a significant risk factor (relative risk, 1.7; 95% CI, 1.2-2.3; *P* = .003) for asthma only in young adults with a history of RSV lower respiratory tract infection during infancy.[@bib40]

Treatment with mAbs specific for RSV F protein (palivizumab and motavizumab) can reduce the risk of RSV-induced bronchiolitis, and several interventional studies have tested whether prevention of RSV-induced bronchiolitis in infancy leads to a reduction in recurrent wheezing and asthma. A prospective nonrandomized study of palivizumab administration to preterm infants in Canada and Europe reported found an 80% reduction in the risk of recurrent wheezing from ages 2 to 5 years in nonatopic children but no effect in atopic children.[@bib41] In a multicenter study conducted in The Netherlands, healthy preterm infants born at 33 to 35 weeks\' gestation were enrolled in a double-blind, placebo-controlled trial of palivizumab prophylaxis and were monitored for 1 year to determine effects on recurrent wheeze. Palivizumab treatment led to a 61% relative reduction in total number of wheezing days in the first year of life.[@bib17] Similarly, a case-control study of palivizumab in Japanese infants with mild prematurity demonstrated reduced recurrent wheezing in the treated versus untreated groups (6.4% vs 18.9%, *P* \< .001).[@bib42] The most recent study evaluated effects of motavizumab on 2127 healthy full-term Navajo infants, an ethnic group at high risk for bronchiolitis. In a double-blind, placebo-controlled randomized trial involving infants aged 6 months or less, motavizumab reduced by 87% the relative risk of hospital admission for bronchiolitis.[@bib43] However, motavizumab did not reduce subsequent rates of medically attended wheezing between the ages of 1 and 3 years (14.9% vs 14.0% in the placebo group).

Thus passive immunization against RSV certainly reduces acute bronchiolitis in preterm infants and likely reduces the rates of recurrent wheezing for premature infants. Whether RSV prophylaxis can reduce recurrent wheezing in term infants is unclear. Additional studies are needed to more clearly understand who might benefit from prophylaxis to reduce recurrent wheezing and also whether this approach can prevent atopic asthma. Given that children who become polysensitized to allergens in infancy are at greatest risk for persistent wheezing and reduced lung function,[@bib5], [@bib17], [@bib44] the latter question is of great clinical importance.

Rhinoviruses {#sec1.3}
------------

Rhinoviruses consist of more than 160 individual types that are classified into 3 species (A, B, and C) based on viral genetics.[@bib45] Rhinoviruses are the pathogens most often associated with upper respiratory tract infections (common colds) and can also cause lower respiratory tract infection and wheezing illnesses.[@bib23], [@bib46], [@bib47] They are the second most common viruses associated with bronchiolitis and are the most common viruses detected in association with wheezing illnesses in children by the age of 1 to 2 years.[@bib48], [@bib49], [@bib50] The species of rhinovirus affects virulence: rhinoviruses A and C cause more severe illnesses in infants[@bib21], [@bib24] and are more likely to cause lower respiratory illnesses.[@bib20], [@bib23] Cadherin-related family member 3 (CDHR3) was recently identified as an entry factor on airway epithelial cells for rhinovirus C.[@bib51] Interestingly, a *CDHR3* polymorphism is associated with the risk for childhood asthma, and the risk allele is associated with more CDHR3 on cell surfaces.[@bib52] This finding suggests the possibility that rhinovirus C infections in early life could contribute to asthma pathogenesis.

For years, it was mistakenly assumed that rhinovirus infections were confined to the upper airway. This assumption was based on early findings that rhinoviruses replicated best at 33°C to 35°C,[@bib53] and it was thought that higher temperatures in the lower airways would preclude lower airway infection. However, temperatures in the large and medium conducting airways are cooler than core temperature and are ideal for rhinovirus replication.[@bib54] Furthermore, some rhinovirus types, including C-species viruses, replicate equally well at 33°C and 37°C.[@bib55], [@bib56] Finally, rhinovirus can be detected in sputum and bronchial biopsy specimens after experimental inoculation of the upper airway,[@bib57], [@bib58], [@bib59] which is concurrent with peak symptoms and reductions in peak expiratory flow.[@bib60] Rhinoviruses have also been detected in lower airway biopsy specimens from infants with recurrent wheezing.[@bib61] These findings provide strong evidence that rhinovirus can infect the lower airways, especially in young children.

Rhinovirus-induced wheezing illnesses in the first 2 to 3 years of life are closely associated with the risk of subsequent asthma. This relationship was first recognized in long-term studies of Finnish infants hospitalized for acute wheezing illnesses. Rhinovirus was the predominant virus detected during wheezing illnesses after 5 months of age. When reassessed 5 years later, 60% of children who wheezed with rhinovirus in the first 2 years of life had asthma.[@bib62] Similar findings were obtained at subsequent follow-up of these children in adolescence.[@bib63] Birth cohort studies have provided definitive evidence of a strong relationship between rhinovirus-induced wheezing and asthma. In the Childhood Origins of Asthma (COAST) study outpatient rhinovirus-induced wheezing illnesses during the first year of life were a significant predictor of recurrent wheezing through age 3 years.[@bib8] Furthermore, viral cause of wheezing illnesses differentially affected the risk for subsequent asthma; the risk of asthma was greater for children who wheezed with rhinovirus (odds ratio \[OR\], 9.8) or children who wheezed with rhinovirus and RSV (OR, 10.0) compared with that in children who wheezed only with RSV (OR, 2.6).[@bib7] Similar findings were reported in the Childhood Asthma Study in Perth: early-life infections with rhinovirus or RSV were associated with an increased risk of asthma but only in children who had aeroallergen sensitization by 2 years of age.[@bib4] In a study conducted in The Netherlands, rhinovirus-induced wheezing episodes were positively related to asthma risk. This relationship was partially explained by lower lung function in infancy being a risk factor for rhinovirus wheezing.[@bib64] Finally, in a collaborative study involving 2 birth cohorts (COAST and Copenhagen Prospective Studies on Asthma in Childhood), the 17q21 genotype strongly influenced both the risk of rhinovirus-induced wheezing and the probability that an infant with rhinovirus-induced wheezing would go on to have asthma.[@bib65] Thus there are unresolved questions as to whether rhinovirus-induced illnesses in childhood promote the development of asthma, reveal the presence of pre-existing asthma, or both.

Bacteria and wheezing illnesses {#sec1.4}
-------------------------------

The previous sections reviewed information linking viral infection with wheezing illnesses and subsequent asthma. Remarkably, the association between airway bacteria and wheezing illnesses might be similarly robust,[@bib10] and this relationship could begin quite early in life. In a Danish birth cohort study colonization of the nasopharynx with *S pneumoniae*, *M catarrhalis*, and *H influenzae* at 1 month of age was associated with increased incidence of recurrent wheeze and asthma in early childhood.[@bib66]

Viral infections can lead to changes in the composition of the airway microbiome and overgrowth of respiratory pathogens, and it is likely that both the virus and secondary changes in airway bacteria contribute respiratory symptoms and perhaps airway obstruction.[@bib11], [@bib67], [@bib68], [@bib69] These findings suggest a potential role for antibiotic treatment for wheezing illnesses in early life; however, the evidence base for this approach appears to be mixed. On one hand, serious bacterial infections accompanying bronchiolitis appear to be rare,[@bib70] and a recent meta-analysis found that antibiotics, such as azithromycin or ampicillin, were not efficacious for treatment of bronchiolitis.[@bib71] On the other hand, Bacharier et al[@bib72] conducted a randomized multicenter clinical trial involving 607 preschool children with a history of recurrent wheezing illnesses who were then treated with azithromycin or placebo at the beginning of respiratory symptoms. Azithromycin treatment reduced the risk of progression to severe lower respiratory illness (hazard ratio, 0.64; 95% CI, 0.41-0.98; *P* = .04). The mechanism of effect could be related to either the antimicrobial or anti-inflammatory activities of macrolide antibiotics. Additional studies are needed to more clearly identify children most likely to respond to azithromycin therapy given the risks of selecting for antibiotic-resistant organisms and the theoretical risks of disturbing the microbiome during infancy.

Although bacterial pathogens are positively associated with wheezing and asthma, environmental exposure to a broad range of bacteria might protect against wheezing illnesses. For example, children exposed to animal sheds on farms are less likely to have wheezing in early life, including transient wheezing of presumed viral origin.[@bib73] These beneficial effects appear to be related to exposure to diverse environmental microbes. Indeed, animal models indicate that gastrointestinal administration of selected bacteria can provide protection against signs of illness after challenge with RSV.[@bib74] Furthermore, exposures in urban environments were related to the risk of recurrent wheeze in the Urban Environment and Childhood Asthma birth cohort study.[@bib75] Dust samples obtained during the first year of life were analyzed for both bacteria and allergen content. Infants with wheezing and atopy by age 3 years were most likely to grow up in homes with reduced exposure to both microbes and specific allergens (cat, mouse, and cockroach). These findings suggest that early-life exposures to bacteria and perhaps animal proteins modulate immune responses that are important determinants of respiratory illness severity.

Interactions between allergy and infections {#sec2}
===========================================

Allergic sensitization, most notably to perennial aeroallergens, has been defined as a pivotal risk factor for the development of asthma.[@bib1] Recently, it has become evident that both the timing of allergic sensitization and the quantity of sensitization are important prognostic indicators. Simpson et al[@bib5] have identified an atopy phenotype in children they termed "multiple early sensitization." In those children sensitized to multiple aeroallergens at an early age, Simpson et al reported a remarkable increase in risk for asthma inception, severe exacerbations leading to hospitalization, and impaired lung function. This link between early-life sensitization to multiple allergens and increased asthma risk has been replicated in additional cohort studies.[@bib6]

This observed link between early sensitization to aeroallergens and asthma risk is in part due to synergy between allergic inflammation and viral infections, most commonly rhinovirus. Indeed, children in the COAST study who were sensitized to aeroallergens and wheezed with rhinovirus during the first 3 years of life had the greatest risk for asthma inception.[@bib7] This led to the question of whether viral illnesses in early life lead to allergic sensitization or whether the converse was true. Using a longitudinal multistate Markov model in the COAST study, Jackson et al[@bib2] identified a sequential relationship whereby allergic sensitization leads to viral wheezing. This relationship was strongest for rhinovirus-induced wheezing, and there was no evidence that viral wheezing led to sensitization.

There is also strong evidence to implicate allergic sensitization and exposure as a risk factor for wheezing with common cold infections later in childhood. In emergency department studies detection of a respiratory tract virus, most commonly rhinovirus, with detectable allergen-specific IgE and/or the presence of eosinophilic inflammation were all identified as risk factors for acute wheezing episodes.[@bib25], [@bib76], [@bib77] Notably, viral infections and allergic inflammation synergistically enhanced the risk of wheezing, and higher levels of allergen-specific IgE conferred the greatest risk. This synergism might be particularly notable for patients with rhinovirus C, in whom aeroallergen sensitization was recently reported as a risk factor for recurrent severe exacerbations leading to emergency department visits and hospitalization.[@bib24]

Mechanisms of allergy-virus interactions {#sec3}
========================================

There are multiple mechanisms by which viral infections are thought to interact with allergic inflammation to lead to lower respiratory airway dysfunction, wheezing, and asthma exacerbations.[@bib78] First, underlying allergic inflammation can directly enhance airway responsiveness to rhinovirus infection.[@bib79] Additionally, viral infections can damage the barrier function of the airway epithelium, leading to enhanced absorption of aeroallergens across the airway wall and enhanced inflammation, whereas underlying allergic inflammation might also lead to enhanced viral replication.[@bib80], [@bib81] Of interest, both rhinovirus infections[@bib60] and allergens[@bib82] can enhance airway epithelial cell production of IL-33, a recently identified innate cytokine, which promotes type 2 airway inflammation and remodeling. This steroid-resistant pathway has been reported to be upregulated in children with difficult-to-control asthma.[@bib82] Interestingly, IL-33 polymorphisms have been linked with intermediate and late-onset wheezing, which are strongly linked to early-life allergic sensitization.[@bib83] Another innate epithelial cytokine, IL-25, is also induced by rhinovirus and is likely to accentuate allergic airway inflammation in the context of rhinovirus infections in allergic subjects.[@bib84]

Finally, there is significant evidence that children with allergic asthma have impaired antiviral responses.[@bib85], [@bib86], [@bib87] Indeed, allergen exposure and high-affinity IgE receptor cross-linking has been shown to impair virus-induced type I and III interferon production in peripheral blood cells ([Fig 1](#fig1){ref-type="fig"} ).[@bib88], [@bib89] The result would be both enhanced viral replication and enhanced type 2 inflammation in the airway.[@bib90], [@bib91] Fig 1Interplay between FcεRI and antiviral responses. In normal airways plasmacytoid dendritic cells (pDCs) are major sources of type I and type III interferons in response to viral infections. These cells also have low-level expression of FcεRI. In the context of allergy, pDCs express greater FcεRI, which is inversely related to interferon responses. In addition, cross-linking of FcεRI further reduces interferon responses. Consequences of suppressed interferon responses to viral infection could include increased viral replication, more severe illnesses with wheezing, and exacerbation of pre-existing asthma.

The most direct evidence to support the importance of allergen-virus interactions in patients with virus-induced wheezing and asthma exacerbations comes from a recent clinical trial of omalizumab (anti-IgE) to prevent seasonal virus-induced asthma exacerbations.[@bib92] In this trial virus-induced exacerbations were significantly reduced by omalizumab, and this reduction coincided with an enhanced type I interferon response *ex vivo* in rhinovirus-stimulated mononuclear cells. Of note, those participants who had larger increases in type I interferon response with omalizumab treatment had the greatest protection from virus-induced exacerbations.

Conclusion {#sec4}
==========

Two key risk factors for the development of childhood asthma are the development of allergic sensitization in early life and wheezing respiratory tract illnesses caused primarily by viruses but also by bacteria either alone or as coinfections accompanying illnesses of viral cause. Therapies directed at these 2 risk factors, either alone or in combination, appear to be essential components to target for development of effective strategies for the primary prevention of asthma in children.What do we know?•Early-life aeroallergen sensitization and viral wheezing illnesses are independent and synergistic risk factors for asthma inception.•Bacterial pathogens have recently emerged as an additional important contributor to asthma risk, either alone or as cofactors with viral infections.What is still unknown?•Whether the prevention of allergic sensitization, antiviral strategies, immunostimulants, or other strategies that augment immune responses to airway pathogens will prevent the development of asthma.
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